Clinical trials: Neonatal Hyperglycaemia
Infant, Low Birth Weight, Hyperglycemia
Gluconeogenesis in Very Low Birth Weight Infants Who Are Receiving Nutrition By Intravenous Infusion
RATIONALE: Very low birth weight infants have problems maintaining normal blood sugar levels. Gluconeogenesis is the production of sugar from amino acids and fats.
- Trial name
- NCT00005889
- Testing
- alanine, amino acids, glucagon
- Where
- United States
- Volunteers
- 96 people
- Sponsor
- National Center for Research Resources (NCRR)
Transient; Hypoglycemia, Neonatal, Preterm
Oral Glibenclamide in Preterm Infants With Hyperglycaemia (GALOP)
The purpose of this study is to confirm hypothesis that Glibenclamide can be administered orally and is an alternative to insulin therapy in treating transient hyperglycemia of premature newborns.
- Conditions
- Transient; Hypoglycemia, Neonatal, Preterm, Glibenclamide Adverse Reaction
- Trial name
- GALOP (NCT05687500)
- Testing
- Glibenclamide, Pharmacokinetics study, C-peptide proinsulin ratio
- Where
- France
- Volunteers
- 35 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Shock, Preterm Birth Complication
Early Hydrocortisone Versus Regular Treatment in Shock in Extremely Preterm Neonates - an Open Randomized Controlled Trial
The goal of this clinical trial is to determine the effectiveness of early use of hydrocortisone (since the diagnosis of shock) for its resolution within the first 72 hours in premature infants under 1,500 g.
- Conditions
- Shock, Preterm Birth Complication, Preterm Intraventricular Hemorrhage, Asphyxia Perinatal
- Trial name
- NCT07248761
- Testing
- Intravascular Hydrocortisone (stress dosage): 1 mg/k/dose each 8 hours for 5 days, Vasoactive drug therapies
- Where
- Mexico
- Volunteers
- 76 people
- Sponsor
- Coordinación de Investigación en Salud, Mexico
Cystic Fibrosis, Diabetes Mellitus
Diabetes Therapy to Improve BMI and Lung Function in CF
To recruit 150 adult patients with cystic fibrosis related diabetes (CFRD) without fasting hyperglycemia for a multi-center, twelve month, placebo-controlled intervention trial testing the ability of insulin or repaglinide to…
- Trial name
- NCT00072904
- Testing
- Insulin Asparte, Repaglinide
- Where
- 7 sites in United States, Canada
- Volunteers
- 108 people, healthy volunteers welcome
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Gestational Diabetes, Diabetes
The DNA Methylation of ARHGEF11 in Macrosomia
Background Macrosomia at birth is associated with subsequent susceptibility to obesity, abnormal glucose metabolism, hypertension and dyslipidaemia.
- Conditions
- Gestational Diabetes, Diabetes, Macrosomia, Fetal
- Trial name
- NCT03165643
- Testing
- OGTT
- Volunteers
- 239 people
- Sponsor
- Peking University First Hospital
Hypoxic Ischemic Encephalopathy of Newborn, Hyperglycemia
Continuous Glucose Monitoring in HIE
The aim of the study is to examine whether the use of continuous glucose monitoring (CGM) to guide the clinical management of glycaemic control will result into an increased time in the target glucose concentration.
- Conditions
- Hypoxic Ischemic Encephalopathy of Newborn, Hyperglycemia, Hypoglycemia
- Trial name
- NCT06563687
- Testing
- Dexcom ONE+
- Where
- 3 sites in Italy
- Volunteers
- 70 people
- Sponsor
- University of Campania Luigi Vanvitelli
Metabolic Syndrome X
Study of Chronic Degenerative Diseases
The prevalence of obesity and type 2 diabetes mellitus (DM) in children have been increasing in parallel at an alarming rate. In particular, the increasing prevalence of type 2 DM is attributable to genetic factors, clinical…
- Trial name
- NCT02495961
- Where
- Mexico
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- Asociación Científica Latina A.C.
Duchenne Muscular Dystrophy
Wearable Technology to Evaluate Hyperglycemia and HRV in DMD
Duchenne muscular dystrophy (DMD) is an X-linked disorder that causes muscle wasting, cardiopulmonary failure, and premature death.
- Trial name
- NCT06124196
- Testing
- wearable technology
- Where
- United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Vanderbilt University Medical Center
Hypoglycemia in Newborn Infants, Hyperglycemia
Hypoglycemic and Hyperglycemic Disorders
Definition of low birth weight: Low birth weight infants are those born weighing less than 2500 g. These are further subdivided into: Very Low Birth Weight : Birth weight <1,500 g Extremely Low Birth Weight : Birth weight <1,000…
- Trial name
- NCT03448965
- Testing
- random blood sugar
- Volunteers
- 100 people
- Sponsor
- Assiut University
Cystic Fibrosis-related Diabetes
EnVision CF Multicenter Study of Glucose Tolerance in Cystic Fibrosis
Cystic Fibrosis Related Diabetes has been identified by the CF community as one of the top ten priorities for CF research. In CF clinical decline due to dysglycemia begins early, prior to diagnosis of diabetes and increases…
- Trial name
- NCT03650712
- Testing
- Oral glucose tolerance test, Continuous glucose monitoring, Dexa scan
- Where
- 4 sites in United States
- Volunteers
- 317 people
- Sponsor
- Katie Larson Ode
Hyperglycaemia
Study of a Model-based Approach to Blood Glucose Control in Very-low-birthweight Neonates
Very low birthweight neonates commonly develop high blood sugar levels. There is an association between high blood sugar levels and poorer short term outcomes but it is not known whether the high sugar level itself actually…
- Trial name
- NCT01419873
- Testing
- Actrapid Human Insulin
- Where
- New Zealand
- Volunteers
- 30 people
- Sponsor
- Christchurch Women's Hospital
Cystic Fibrosis Related Diabetes
Insulin Glargine Vs Standard Insulin Therapy
This Study is designed to determine whether treatment of CFRD with glargine insulin will improve hemoglobin A1c, weight and muscle mass compared to the traditional regimen of bedtime NPH insulin.
- Trial name
- NCT00222521
- Testing
- Glargine insulin
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Minnesota
Cystic Fibrosis, Glucose Metabolism Disorders
One Year Glargine Treatment in CFRD Children and Adolescents
Glargine treatment can improve the clinical features in Cystic Fibrosis patients affected by glucose derangements
- Trial name
- NCT00483769
- Testing
- Glargine
- Where
- Italy
- Volunteers
- 20 people
- Sponsor
- Federico II University
Very Low Birth Weight Infant, Very Preterm Maturity of Infant
CGM Use in Preterm Infants
Preterm infants (gestational age (GA) at birth < 31 weeks) admitted to the University of Minnesota Masonic Children's Hospital NICU will have a Dexcom G6 sensor Continuous Glucose Monitor (CGM) placed shortly after consent and…
- Conditions
- Very Low Birth Weight Infant, Very Preterm Maturity of Infant, Hyperglycemia
- Trial name
- NCT05436925
- Testing
- Dexcom G6 sensor Continuous Glucose Monitor (CGM)
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of Minnesota
Duchenne Muscular Dystrophy
Wearable Technology to Evaluate Hyperglycemia and HRV in DMD - Longitudinal Aim
Duchenne Muscular Dystrophy (DMD) is an X-linked disorder that causes muscle wasting, cardiopulmonary failure, and premature death.
- Trial name
- NCT06093100
- Testing
- wearable technology
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Vanderbilt University Medical Center
Hyperglycemia, Hypoglycemia
Continous Glucose Monitoring in Neonates at Risk of Hypoglycaemia- a Feasibility Study
The study's main purpose is to test feasibility of Continous Glucose montoring in Neonates during the first 72 hrs.
- Conditions
- Hyperglycemia, Hypoglycemia, Hypoglycemia Neonatal
- Trial name
- CSBS I (NCT07375615)
- Testing
- Continous glucose monitor
- Where
- Norway
- Volunteers
- 25 people
- Sponsor
- Sykehuset Innlandet HF
Cystic Fibrosis Homozygous for Phe 508 Del CFTR, Glucose Intolerance or Newly Diagnosis Diabetes
Observational Study of Glucose Tolerance Abnormalities in Patient With Cystic Fibrosis Homozygous for Phe 508 Del CFTR Treated by Lumacaftor-Ivacaftor
Cystic Fibrosis related diabetes (CFRD), a major factor of morbid-mortality in CF, is characterized by a preclinical phase of glucose intolerance particularly long reaching up to 10 years.
- Trial name
- GLUCORRECTOR (NCT03512119)
- Testing
- Lumacaftor-Ivacaftor treatment
- Where
- 13 sites in France
- Volunteers
- 55 people
- Sponsor
- University Hospital, Strasbourg, France
Cystic Fibrosis
Muscle Accrual and Function in Cystic Fibrosis-Impact of Glucose Intolerance
This study will investigate the link between glucose abnormalities and elements critical to muscle function including mass, composition and energy metabolism.
- Trial name
- NCT02776098
- Where
- 2 sites in United States
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Children's Hospital of Philadelphia
Heart Defects, Congenital, Hyperglycemia
SPECS: Safe Pediatric Euglycemia in Cardiac Surgery
Critically ill children, including children undergoing heart surgery, commonly develop elevated blood glucose (also known as "blood sugar") levels during their illness, which can lead to poor health outcomes and an increased risk…
- Trial name
- SPECS (NCT00443599)
- Testing
- Insulin, Usual Care
- Where
- 2 sites in United States
- Volunteers
- 989 people
- Sponsor
- Boston Children's Hospital
Obesity, Abdominal Obesity
Adiponectin, ICAM-1, VCAM-1 Levels and Metabolic Syndrome in Obese Adolescents
Adipose tissue secreting a number of adipokines which regulate insulin sensitivity, energy metabolism and vascular homeostasis, so the dysfunction of adipose tissue is linked with the incidence of obesity accompanied with insulin…
- Conditions
- Obesity, Abdominal Obesity, Metabolic Syndrome, Hypertension
- Trial name
- ICAM; VCAM (NCT05685017)
- Testing
- Nur Aisiyah Widjaja
- Where
- Indonesia
- Volunteers
- 125 people, healthy volunteers welcome
- Sponsor
- Universitas Airlangga